Drugs / NG-monomethyl-L-arginine (L-NMMA)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01070940 Comparator | Feb → Jun 2010 | — | Regional Hospital Holstebro | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NG-monomethyl-L-arginine (L-NMMA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01070940 ↗ |
| Known as | L-NMMA | “NG-monomethyl-L-arginine (L-NMMA)” NCT01070940 ↗ |
| Action | Inhibit | “L-NMMA, an inhibitor of the nitric oxide synthase” NCT01070940 ↗ |
| Route | Intravenous | “3 mg/kg IV priming dose + 2 mg/kg/hr IV infusion for 1 hour” NCT01070940 ↗ |